Phare Bio and Basilea Announce Landmark Partnership to Develop Next-Generation Broad-Spectrum Antibiotic Using AI

Core Insights - Phare Bio and Basilea Pharmaceutica have formed a strategic partnership to develop a novel broad-spectrum antibiotic targeting high-priority gram-negative pathogens, addressing critical unmet medical needs [1][2] - This collaboration is a pioneering effort in antibiotic research, emphasizing the integration of patient needs and target product profiles in AI-driven drug discovery [2][3] - Phare Bio will utilize its generative AI platform to design drug-like molecules, while Basilea will handle further development and commercialization, creating a new model for antibiotic innovation [3][4] Company Overview - Phare Bio is a biotech social venture established in 2020, focused on using AI to combat antibiotic resistance and accelerate the discovery of new antibiotics [5] - Basilea Pharmaceutica, founded in 2000 and based in Switzerland, specializes in developing innovative drugs for severe bacterial and fungal infections, with existing products like Cresemba and Zevtera [6]